Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jun;6(3):100135.
doi: 10.1016/j.esmoop.2021.100135. Epub 2021 Apr 27.

Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices

M Bartoletti  1 , S C Cecere  2 , L Musacchio  3 , R Sorio  1 , F Puglisi  4 , S Pignata  2
Affiliations
Editorial

Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices

M Bartoletti et al. ESMO Open. 2021 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure FP reports grants from AstraZeneca, grants, personal fees and other from Roche, personal fees and other from Eli Lilly, personal fees from Amgen, personal fees from Ipsen, personal fees from Merck Sharp & Dohme (MSD), personal fees from Takeda, grants and other from Eisai, other from Novartis and Pfizer, outside the submitted work. SP reports grants from Roche; personal fees from Roche, grants and personal fees from MSD, grants and personal fees from AZ, personal fees from Clovis, personal fees from GlaxoSmithKline, personal fees from Pharmamar, grants and personal fees from Pfizer, outside the submitted work. All other authors have declared no conflicts of interest.

References

    1. Ledermann J., Harter P., Gourley C. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–1392. - PubMed
    1. Pujade-Lauraine E., Ledermann J.A., Selle F. SOLO2/ENGOT-Ov21 investigators, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–1284. - PubMed
    1. Mirza M.R., Monk B.J., Herrstedt J. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–2164. - PubMed
    1. Coleman R.L., Oza A.M., Lorusso D. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–1961. - PMC - PubMed
    1. Poveda A., Floquet A., Ledermann J.A. Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2020;38:6002.

Publication types

MeSH terms

Substances